Company intelligence / Profile preview
Twist Bioscience
- Ownership
- Public · TWST
- Employees
- ~900
- Development stage
- Other
Overview
Twist’s core business provides commercial-scale synthetic DNA and related products globally. Its platforms are foundational tools for drug discovery/development but not direct therapeutic developers except through partnerships/subsidiaries like Revelar Biotherapeutics. The first antibody program from this pipeline was expected to enter clinical studies in or after 2022; no large-scale late-stage clinical results reported as of June 2025.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Synthetic oligonucleotideAntibodyRecombinant proteinSmall moleculeDNA-based data storage
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $7.9B
- Total revenue
- $376.6M
- Enterprise value
- $7.9B
Beyond the preview
Go deeper on Twist Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Twist Bioscience.